Important:
Information contained in the following UpToDate Talk podcasts was current at the time of initial release. However, this content is not maintained or updated. For current clinical recommendations, please always consult UpToDate Online. Please note that we are no longer producing new clinical podcasts.
UpToDate faculty discuss important changes to the practice of medicine based in our clinical podcasts. Our contributors are recognized physician leaders in their fields and offer their expertise regarding each update and its impact on clinical practice.
Support for UpToDate Talk is provided by UpToDate, Wolters Kluwer. UpToDate is entirely funded by the subscriptions of its users and does not accept advertising or funding unrelated to subscriptions. The opinions in such podcasts are entirely those of the discussants, and these discussants are authors and editors for UpToDate. View the UpToDate conflict of interest policy.
This is the complete archive for the UpToDate Clinical Talk Podcasts.
Complications of t1 and t2 diabetes diagnosed in childhood; Gene therapy for sickle cell disease
Date Released: Jun 28 2017
Dr. Joseph Wolfsdorf discusses complications related to type 1 and type 2 diabetes in pediatric patients, and Dr. Michael DeBaun discusses a report of gene therapy for sickle cell disease. Dr. Nancy Sokol hosts.
Dr. Joseph Wolfsdorf is a Professor of Pediatrics at Harvard Medical School, and Director of the Diabetes Program at the Boston Children's Hospital.
Dr. Michael DeBaun is a Professor of Pediatrics and Medicine at Vanderbilt University and is Director of the Vanderbilt-Meharry Center for Excellence in Sickle Cell Disease.Segment on diabetes in children (Dr. Wolfsdorf):
- Dabelea D, Stafford JM, Mayer-Davis EJ, et al. Association of Type 1 Diabetes vs Type 2 Diabetes Diagnosed During Childhood and Adolescence With Complications During Teenage Years and Young Adulthood. JAMA 2017; 317:825.
Segment on gene therapy for sickle cell disease (Dr. DeBaun):
- Ribeil JA, Hacein-Bey-Abina S, Payen E, et al. Gene Therapy in a Patient with Sickle Cell Disease. N Engl J Med 2017; 376:848.
Joseph I Wolfsdorf, MB, BCh Nothing to disclose
Michael R DeBaun, MD, MPH Nothing to disclose
Long-term follow-up of imatinib for CML; Ocrelizumab for primary progressive multiple sclerosis
Date Released: Jun 14 2017
This episode features Dr. Richard Larson discussing the long-term outcomes of imatinib treatment for chronic myeloid leukemia, and Dr. Francisco Gonzalez-Scarano discussing the use of ocrelizumab for treatment of primary progressive multiple sclerosis. Dr. Jennifer Mitty hosts.
Dr. Francisco González-Scarano is Professor of Neurology and the John P. Howe Distinguished Chair in Health Policy at the University of Texas Health Science Center at San Antonio and Professor Emeritus of Neurology at the University of Pennsylvania.
Dr. Richard Larson is Professor of Medicine and the Director of the Hematological Malignancies Clinical Research Program at the University of Chicago Pritzker School of Medicine.Segment on Long-term follow-up of Imatinib in chronic myeloid leukemia (Dr. Richard Larson) :
- Hochhaus A, Larson RA, Guilhot F, et al. Long-term Outcomes of Imatinib Treatment for Chronic Myeloid Leukemia. N Engl J Med 2017; 376:917.
Segment on Ocrelizumab for primary progressive multiple sclerosis (Dr. Francisco González-Scarano):
- Montalban X, Hauser SL, Kappos L, et al. Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis. N Engl J Med 2017; 376:209.
Francisco González-Scarano, MD Equity Ownership/Stock Options: Multiple, but traded by advisors without personal input [Pharmaceutical]. Other Financial Interests: NeuroLink [Venture Capital].
Richard A Larson, MD Grant/Research/Clinical Trial Support: Amgen [leukemia (blinatumomab)]; Astellas [leukemia (gilteritinib)]; Erytech [leukemia (eryaspase)]; Ariad [leukemia (ponatinib)]; Novartis [leukemia (nilotinib)]; Ambit Bioscience [leukemia (quizartinib)]; Daiichi Sankyo [leukemia (quizartinib)]; Celgene [leukemia (AG-221)]. Consultant/Advisory Boards: Novartis [leukemia (imatinib, nilotinib)]; Ariad Data Safety Monitoring Board [leukemia (ponatinib)]; CVS/Caremark [leukemia (drug prior authorization program)]; Pfizer [leukemia (gemtuzumab ozogamicin, inotuzumab)]; Celgene Data Safety Monitoring Board [leukemia (azacitidine, durvalumab)]; Bristol Meyers Squibb Data Safety Monitoring Board [leukemia (dasatinib)]; Amgen [leukemia (blinatumomab)]; Astellas [leukemia (gilteritinib)]; Jazz [leukemia (CPX-351)].
UpToDate Pathways: Management of anticoagulation for patients with nonvalvular atrial fibrillation
Date Released: Jun 7 2017
This episode features Dr. Mark Estes discussing an approach to optimizing anticoagulation choices for patients with nonvalvular atrial fibrillation. Dr. Nancy Sokol hosts. Listen to the full podcast by pressing the Play Button below.
Dr. Mark Estes is Professor of Medicine at Tufts University School of Medicine and Director of the New England Cardiac Arrhythmia Center at Tufts Medical Center in Boston.N A Mark Estes, III, MD Disclosure: Consultant/Advisory Boards: Medtronic [Arrhythmias (pacemakers and ICDs)]; St. Jude Medical [Arrhythmias (pacemakers and ICDs)]; Boston Scientific [Arrhythmias (pacemakers and ICDs)].
UpToDate Pathways: Initial management of hypertension
Date Released: Jun 7 2017
This episode features Dr. George Bakris discussing the initial management of hypertension and factors that should be considered in optimizing initial therapy for an individual patient. Dr. Nancy Sokol hosts. Listen to the full podcast by pressing the Play Button below.
Dr. George Bakris is Professor of Medicine at the University of Chicago where he directs the Comprehensive Hypertension Center.George Bakris, MD Grant/Research/Clinical Trial Support: Bayer; Boehringer Ingelheim; Relypsa; Vascular Dynamics [Diabetic neuropathy, diabetes, hypertension (Empagliflozin, patiromer)]. Consultant/Advisory Boards: AstraZeneca; Bayer; Boehringer Ingelheim; Relypsa; Vascular Dynamics; Merck; Pfizer; NxStage [Diabetic neuropathy, diabetes, hypertension (Empagliflozin, patiromer)].